{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:57:21Z","timestamp":1777532241572,"version":"3.51.4"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T00:00:00Z","timestamp":1454371200000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n          <jats:p>Lungenkrebs ist eine h\u00e4ufige Erkrankung, die v.\u00a0a. im h\u00f6heren Alter auftritt. Die M\u00f6glichkeiten der medikament\u00f6sen Behandlung dieser Tumoren haben sich in den letzten 10\u00a0Jahren deutlich erweitert. F\u00fcr bestimmte molekulare Subgruppen kann heute eine gezielte Therapie das \u00dcberleben der Patienten relevant verbessern. Aktuell finden Immuntherapeutika wie PDL1 (\u201eprogrammed death ligand\u201c)\/PD1 (\u201eprogrammed cell death protein\u00a01 receptor\u201c)-Antik\u00f6rper Eingang in die Klinik, die bei einer Subgruppe von Patienten zu einem deutlich verl\u00e4ngerten \u00dcberleben f\u00fchren k\u00f6nnen. Aufgrund der hohen Inzidenz des Lungenkarzinoms einerseits und von rheumatischen Erkrankungen andererseits treten diese Erkrankungen immer wieder auch gemeinsam auf und erfordern ein interdisziplin\u00e4res Management. Die Erfolge der verbesserten Therapie des Lungenkarzinoms f\u00fchren dazu, dass auch die Behandlung von begleitenden Erkrankungen wieder mehr in den Fokus r\u00fcckt. Andererseits kann der Eingriff in das Immunsystem durch die Immuncheckpoint-Inhibitoren zu neuen Herausforderungen bei gleichzeitig bestehenden Autoimmunerkrankungen f\u00fchren. Die M\u00f6glichkeit eines effektiven Lungenkarzinomscreenings in der Zukunft stellt ebenfalls eine Verbesserung der Mortalit\u00e4t in Aussicht. Daher ergibt sich auch bei Patienten mit rheumatoider Arthritis die Frage nach einer optimalen \u00dcberwachung unter immunsuppressiver Therapie. Ziel dieses Reviews ist es, die Interaktion der beiden Erkrankungen Lungenkarzinom und rheumatoide Arthritis im Hinblick auf die aktuelle Datenlage zu diskutieren.<\/jats:p>","DOI":"10.1007\/s00393-016-0043-0","type":"journal-article","created":{"date-parts":[[2016,2,2]],"date-time":"2016-02-02T10:37:56Z","timestamp":1454409476000},"page":"47-53","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lungenkarzinom und rheumatoide Arthritis","Lung cancer and rheumatoid arthritis"],"prefix":"10.1007","volume":"75","author":[{"given":"A.","family":"Rubbert-Roth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Zander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kneitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Baerwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Wirtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,2]]},"reference":[{"issue":"5","key":"43_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa1102873","volume":"365","author":"DR Aberle","year":"2011","unstructured":"Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, National Lung Screening Trial Research Team et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395\u2013409","journal-title":"N Engl J Med"},{"key":"43_CR2","volume-title":"Krebsatlas der Bundesrepublik Deutschland 1981\u20131990","author":"N Becker","year":"1998","unstructured":"Becker N, Wahrendorf J (1998) Krebsatlas der Bundesrepublik Deutschland 1981\u20131990. Springer, Berlin Heidelberg New York. www.krebsatlas.de"},{"issue":"3","key":"43_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"P Bidoli","year":"2012","unstructured":"Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M et al (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13(3):247\u2013255","journal-title":"Lancet Oncol"},{"issue":"1","key":"43_CR4","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.lungcan.2013.02.018","volume":"81","author":"M Bos","year":"2013","unstructured":"Bos M, Gardizi M, Schildhaus HU, Heukamp LC, Geist T, Kaminsky B et al (2013) Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib. Lung Cancer 81(1):142\u2013143","journal-title":"Lung Cancer"},{"issue":"2","key":"43_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer J, Reckamp KL, Baas P, Crin\u00f3 L, Eberhardt WEE, Poddubskaya E et al (2015) Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373(2):123\u2013135","journal-title":"N Engl J Med"},{"issue":"15","key":"43_CR6","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1200\/JCO.2012.45.9867","volume":"31","author":"R Buettner","year":"2013","unstructured":"Buettner R, Wolf J, Thomas RK (2013) Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol Am Soc Clin Oncol 31(15):1858\u20131865","journal-title":"J Clin Oncol Am Soc Clin Oncol"},{"issue":"1","key":"43_CR7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1517\/14740338.2014.973400","volume":"14","author":"M Burotto","year":"2015","unstructured":"Burotto M et al (2015) Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma. Expert Opin Drug Saf 14(1):97\u2013110","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl 10","key":"43_CR8","first-page":"32","volume":"67","author":"K Chatzidionysiou","year":"2015","unstructured":"Chatzidionysiou K et al (2015) Risk for lung cancer in RA and different RA phenotypes: results from a population based case-control study (abstract). Arthritis Rheumatol 67(Suppl 10). http:\/\/acrabstracts.org\/abstract\/risk-for-lung-cancer-in-ra-and-different-ra-phenotypes-results-from-a-population-based-case-control-study\/","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"43_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2015.07.016","volume":"90","author":"JC Chuang","year":"2015","unstructured":"Chuang JC, Neal JW, Niu X\u2011M, Wakelee HA (2015) Adjuvant therapy for EGFR mutant and ALK positive NSCLC: current data and future prospects. Lung Cancer 90(1):1\u20137","journal-title":"Lung Cancer"},{"issue":"Supplement 2","key":"43_CR10","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/s-0029-1243837","volume":"64","author":"Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin","year":"2010","unstructured":"Deutsche Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin, Deutsche Krebsgesellschaft (2010) Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms Interdisziplin\u00e4re S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin und der Deutschen Krebsgesellschaft. Pneumologie 64(Supplement 2):e1\u2013e164. doi:10.1055\/s-0029-1243837","journal-title":"Pneumologie"},{"issue":"1","key":"43_CR11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1136\/annrheumdis-2012-201969","volume":"72","author":"L Dreyer","year":"2013","unstructured":"Dreyer L, Mellemkj\u00e6r L, Andersen AR, Bennett P, Poulsen UE et al (2013) Incidences of overall and site specific cancers in TNF\u03b1 inhibitor treated patients with rheumatoid arthritis and other arthritides \u2013 a follow-up study from the DANBIO registry. Ann Rheum Dis 72(1):79\u201382","journal-title":"Ann Rheum Dis"},{"key":"43_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1164\/ajrccm.161.1.9906062","volume":"161","author":"R Hubbard","year":"2000","unstructured":"Hubbard R et al (2000) Lung cancer and crytogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 161:5\u20138","journal-title":"Am J Respir Crit Care Med"},{"key":"43_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1136\/ard.2008.102962","volume":"69","author":"E Karlson","year":"2010","unstructured":"Karlson E et al (2010) Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann Rheum Dis 69:54\u201360","journal-title":"Ann Rheum Dis"},{"issue":"25","key":"43_CR14","doi-asserted-by":"publisher","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","volume":"362","author":"M Maemondo","year":"2010","unstructured":"Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380\u20132388","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"43_CR15","doi-asserted-by":"publisher","first-page":"S156","DOI":"10.3978\/j.issn.2072-1439.2015.04.19","volume":"7","author":"MW Marcus","year":"2015","unstructured":"Marcus MW, Raji OY, Field JK (2015) Lung cancer screening: identifying the high risk cohort. J Thorac Dis 7(Suppl 2):S156\u2013S162. doi:10.3978\/j.issn.2072-1439.2015.04.19","journal-title":"J Thorac Dis"},{"key":"43_CR16","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/rheumatology\/kes350","volume":"52","author":"LK Mercer","year":"2013","unstructured":"Mercer LK et al (2013) Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 52:91\u201398","journal-title":"Rheumatology"},{"key":"43_CR17","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1136\/annrheumdis-2013-204851","volume":"74","author":"LK Mercer","year":"2015","unstructured":"Mercer LK et al (2015) Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. Ann Rheum Dis 74:1087\u20131093","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"43_CR18","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2):175\u2013180","journal-title":"Lancet Oncol"},{"issue":"21","key":"43_CR19","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"L Paz-Ares","year":"2008","unstructured":"Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552\u20133559","journal-title":"J Clin Oncol"},{"issue":"7","key":"43_CR20","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1002\/art.30247","volume":"63","author":"P Raaschou","year":"2011","unstructured":"Raaschou P, Simard JF, Neovius M, Askling J (2011) Anti-rheumatic therapy in Sweden study group. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents. Arthritis Rheumatol 63(7):1812\u20131822","journal-title":"Arthritis Rheumatol"},{"key":"43_CR21","volume-title":"Krebs in Deutschland 2009\/2010","author":"Robert Koch-Institut","year":"2013","unstructured":"Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg) (2013) Krebs in Deutschland 2009\/2010, 9.\u00a0Ausgabe. Robert Koch-Institut, Berlin","edition":"9"},{"issue":"3","key":"43_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239\u2013246","journal-title":"Lancet Oncol"},{"key":"43_CR23","unstructured":"Rubbert-Roth A, Sebba A, Brockwell L, Kelman A, Porter-Brown B. Malignancy rates in patients with rheumatoid arthritis treated with tocilizumab (Manuscript submitted)"},{"issue":"24","key":"43_CR24","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550","journal-title":"N Engl J Med"},{"issue":"3","key":"43_CR25","first-page":"31","volume":"3","author":"R Schmerzling","year":"2014","unstructured":"Schmerzling R (2014) Toxicity of checkpoint inhibitors. Chin Clin Oncol 3(3):31","journal-title":"Chin Clin Oncol"},{"issue":"2","key":"43_CR26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.lungcan.2013.11.016","volume":"83","author":"L Shi","year":"2014","unstructured":"Shi L et al (2014) Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials. Lung Cancer 83(2):231\u2013239","journal-title":"Lung Cancer"},{"key":"43_CR27","doi-asserted-by":"publisher","first-page":"5216","DOI":"10.1200\/JCO.2006.07.1381","volume":"24","author":"C Siemes","year":"2006","unstructured":"Siemes C et al (2006) C\u2011reactive protein levels, variation in the C\u2011reactive protein gene and cancer risk: the Rotterdam study. J Clin Oncol 24:5216\u20135222","journal-title":"J Clin Oncol"},{"key":"43_CR28","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1136\/ard.2008.097527","volume":"68","author":"TA Simon","year":"2009","unstructured":"Simon TA et al (2009) Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 68:1819\u20131826","journal-title":"Ann Rheum Dis"},{"key":"43_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar2404","volume":"10","author":"AL Smitten","year":"2008","unstructured":"Smitten AL et al (2008) A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther 10:1\u20138","journal-title":"Arthritis Res Ther"},{"issue":"23","key":"43_CR30","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","volume":"371","author":"BJ Solomon","year":"2014","unstructured":"Solomon BJ, Mok T, Kim D\u2011W, Wu Y\u2011L, Nakagawa K, Mekhail T et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371(23):2167\u20132177","journal-title":"N Engl J Med"},{"key":"43_CR31","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/ar2904","volume":"12","author":"A Strangfeld","year":"2010","unstructured":"Strangfeld A et al (2010) Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"43_CR32","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.201410-1777CI","volume":"191","author":"LT Tanoue","year":"2015","unstructured":"Tanoue LT, Tanner NT, Gould MK, Silvestri GA (2015) Lung cancer screening. Am J Respir Crit Care Med 191(1):19\u201333","journal-title":"Am J Respir Crit Care Med"},{"issue":"26","key":"43_CR33","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366(26):2443","journal-title":"N Engl J Med"},{"key":"43_CR34","unstructured":"Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. IARC WHO Classification of Tumours, No 7"},{"issue":"10","key":"43_CR35","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.3899\/jrheum.150051","volume":"42","author":"R Van Vollenhoven","year":"2015","unstructured":"Van Vollenhoven R et al (2015) Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 42(10):1761\u20131766","journal-title":"J Rheumatol"},{"key":"43_CR36","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.3899\/jrheum.141210","volume":"42","author":"K Yamamoto","year":"2015","unstructured":"Yamamoto K et al (2015) Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 42:1368\u20131375","journal-title":"J Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-016-0043-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0043-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-016-0043-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:10:38Z","timestamp":1630613438000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-016-0043-0"}},"subtitle":["Eine\u00a0interdisziplin\u00e4re Herausforderung","An interdisciplinary challenge"],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["43"],"URL":"https:\/\/doi.org\/10.1007\/s00393-016-0043-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"2 February 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Dieses Manuskript entstand auf Basis einer von Roche und Chugai unterst\u00fctzten Arbeitsgruppe (Systemerkrankung RA), aber ohne jegliche Einflussnahme der Firmen auf das Ergebnis oder die Publikation. A.\u00a0Rubbert-Roth erhielt Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von Abbvie, BMS, Chugai, Roche, MSD, UCB, Pfizer, Boehringer, Novartis, Lilly. T.\u00a0Zander erhielt Unterst\u00fctzung im Rahmen von Advisory Boards von Merck, Boehringer, Lilly, Roche, Novartis, Amgen. C.\u00a0Baerwald erhielt Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von Abbvie, BMS, Chugai, MSD, Mundipharma, Pfizer, Roche, UCB. C.\u00a0Witt erhielt Honorare f\u00fcr Vortr\u00e4ge und Advisory Boards von MSD, Pfizer, Astra-Zeneca, GSK, Berlin-Chemie, Tesa, Freudenberg und BMS. C.\u00a0Kneitz und H.\u00a0Wirtz geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}